Abstract: |
Opioid tolerance can be modulated by the N-methyl-D-aspartate/nitric oxixde (NMDA/NO) cascade. Evidence exploring a daily injection paradigm indicates that agents antagonizing NMDA receptors can prevent tolerance to morphine and delta drugs, but not kappa agents. Drugs work regardless of whether they act as competitive or noncompetitive antagonists. Even an agent acting as an antagonist on the glycine site of the NMDA receptor is effective. Blockade of nitric oxide synthase has similar effects on opioid tolerance, preventing morphine and delta tolerance but not that of kappa drugs. Even methylene blue, which can inhibit guanylyl cyclase activity, is effective, presumably by blocking cGMP formation resulting from NO release. These results demonstrate the importance of an intact NMDA/NO cascade in the production of opioid tolerance and open new possibilities in the design of agents acting on opioid tolerance. © 1995 American College of Neuropsychopharmacology. |
Keywords: |
review; nonhuman; methylene blue; mouse; animals; opiate; animal experiment; enzyme inhibitors; opioids; morphine; opioid-related disorders; analgesia; drug tolerance; arginine; nitric oxide synthase; nitroarginine; tolerance; opiate addiction; opioid receptor; n methyl dextro aspartic acid receptor; nitric oxide; receptors, opioid, delta; receptors, n-methyl-d-aspartate; dependence; withdrawal; excitatory amino acid antagonists; subcutaneous drug administration; narcotics; priority journal; receptors, opioid, kappa; substance withdrawal syndrome; nmda; 2 amino 4,5 (1,2 cyclohexyl) 7 phosphonoheptanoic acid
|